Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $39.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target hoisted by Cantor Fitzgerald from $33.00 to $39.00 in a research report report published on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company downgraded Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $50.00 to $18.00 in a report on Thursday, September 3rd. TD Cowen reduced their price objective on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. William Blair downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Thursday, September 3rd. Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Finally, Jefferies Financial Group dropped their target price on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $34.42.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $14.51 on Friday. The company has a market cap of $1.43 billion, a PE ratio of -2.48 and a beta of 0.31. The stock has a 50-day moving average of $23.88 and a 200-day moving average of $24.43. Ultragenyx Pharmaceutical has a 52-week low of $12.73 and a 52-week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same period last year, the business earned ($1.17) EPS. The firm’s revenue was up 28.5% compared to the same quarter last year. On average, research analysts predict that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $355,746,000. Assenagon Asset Management S.A. raised its stake in Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after purchasing an additional 2,057,951 shares during the last quarter. Norges Bank acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at $29,004,000. Bank of America Corp DE bought a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at $38,347,000. Finally, Jefferies Financial Group Inc. bought a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at $31,040,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA granted full approval to FAYUVI for pediatric patients with Sanfilippo syndrome Type A, also known as MPS IIIA. It is the first approved treatment for the fatal neurodegenerative disease, creating a new commercial opportunity for Ultragenyx where no prior therapy existed. Clinical data showed durable benefit, including a 23.5-point cognitive advantage versus natural history in the pivotal analysis. Ultragenyx Announces Approval of FAYUVI Gene Therapy
• Positive Sentiment: FAYUVI carries a reported $3.95 million list price, potentially making it a significant revenue contributor despite the disease’s small patient population. Ultragenyx expects shipments to qualified treatment centers within 30–60 days and will provide insurance and treatment-access support through its UltraCare program. Ultragenyx Sets $3.95m List Price for Fatal Rare Disease Therapy
• Positive Sentiment: The approval is Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company also received a Priority Review Voucher, which could accelerate development or potentially have financial value. US FDA Approves Ultragenyx’s Gene Therapy
• Positive Sentiment: Analysts raised targets after the approval: Cantor Fitzgerald and Canaccord Genuity moved to $39, Citi to $32, and Morgan Stanley to $20. Citi and Canaccord maintained bullish ratings, while Morgan Stanley remained equal weight. Ultragenyx Stock Jumps on Fayuvi Approval and Analyst Target
• Neutral Sentiment: The commercial opportunity is promising but limited by the ultra-rare population. Successful sales will depend on identifying eligible children, establishing treatment centers, securing insurer reimbursement, and managing the complexity of one-time gene-therapy administration.
• Negative Sentiment: FAYUVI’s label includes risks such as liver toxicity, low platelet counts, infusion reactions, thrombotic microangiopathy, and potential malignancy. Long-term safety and real-world adoption remain important uncertainties.
• Negative Sentiment: A Pomerantz law-firm investigation adds an overhang, while the earlier failed Angelman syndrome trial remains a reminder of Ultragenyx’s clinical-development risk. Pomerantz Investor Alert

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.